Can DMT treat depression?

What the phase II trial showed

A controlled phase II clinical trial tested one of the primary psychoactive components traditionally used in ayahuasca ceremonies and reported encouraging reductions in depressive symptoms among participants. The compound produced measurable improvements compared with baseline, prompting researchers to describe the results as ‘promising.’ The study represents a step beyond early, small-scale investigations by assessing both therapeutic effect and tolerability in a larger, more structured clinical setting.

How the treatment might work and what is still unknown

The compound is a rapid-acting psychedelic molecule that alters consciousness during brief dosing sessions. That acute state is thought to enable psychological processing and may trigger downstream biological changes that ease mood disorders, but the precise mechanisms and their durability are not yet established. Important open questions remain:

• How long symptom improvement lasts after dosing
• The optimal dose, frequency, and clinical setting for administration
• How risks and benefits compare with standard antidepressants and other rapid-acting treatments
• Safety in broader, more medically complex populations

Why this matters now

Current antidepressant options do not work for everyone and often take weeks to act. Rapid-acting approaches could fill an important treatment gap if they prove safe and reproducible. However, the evidence to date is preliminary: phase II signals need confirmation in larger phase III trials that include diverse participants, blinded controls, standardized psychotherapeutic support, and long-term follow-up. Regulators will also need clear safety and risk-management plans before any routine clinical use.